NDA 217779 · Geron
Rytelo
Imetelstat Sodium · Intravenous
NovelOrphanCDER novel approval, Jun 6, 2024: To treat low- to intermediate-1 risk myelodysplastic syndromes
Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jun 6, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
46
4 Phase 3, 2 recruiting
FAERS reports
186
103 serious, 11 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 22, 2026.
1. INDICATIONS AND USAGE RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). ( 1 )
Mechanism: Imetelstat is an oligonucleotide human telomerase inhibitor that binds to the template region of the RNA component of human telomerase (hTR), inhibits telomerase enzymatic activity and prevents telomere binding. Increased telomerase activity and human telomerase reverse transcriptase (hTERT) RNA expression have been reported in MDS and malignant stem and progenitor cells. Nonclinical studies showed imetelstat treatment led to reduction of telomere length, reduction of malignant stem and progenitor cell proliferation, and induction of apoptotic cell death.
Therapeutic areas: Hematology and blood cancers · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 6, 2024 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelMedication GuideLetter
2 products under this application
- RYTELO · IMETELSTAT SODIUM EQ 47MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
- RYTELO · IMETELSTAT SODIUM EQ 188MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Imetelstat" as an intervention, any sponsor and status, largest first.
- MONET1-MOtesanib NSCLC Efficacy and Tolerability StudyPivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT00460317 · 1,450 participants · Start Jul 2007 · Primary completion Mar 2011
Drug: AMG 706; placebo and 2 more · For: Non-Small Cell Lung Cancer
- Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung CancerPivotal-lookingTerminated
TakedaTakeda (TAK)
NCT02629848 · 401 participants · Start Jul 2012 · Primary completion Sep 2014
Drug: Motesanib; Placebo and 2 more · For: Carcinoma, Non-Small-Cell Lung
- A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentPivotal-lookingActive, not recruiting
Geron CorporationIndustry
NCT04576156 · 327 participants · Start Apr 12, 2021 · Primary completion Jun 30, 2028
Drug: Imetelstat; Best Available Therapy (BAT) · For: Myelofibrosis
Sites: La Jolla, California; Los Angeles, California; New Haven, Connecticut · 144 sites in all
- Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Pivotal-lookingActive, not recruiting
Geron CorporationIndustry
NCT02598661 · 289 participants · Start Jan 12, 2016 · Primary completion Oct 13, 2023
Drug: Imetelstat Sodium; Placebo · For: Myelodysplastic Syndromes
Sites: Birmingham, Alabama; Tucson, Arizona; Bakersfield, California · 126 sites in all
- A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast CancerPivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT00356681 · 282 participants · Start Dec 2006 · Primary completion Feb 2009
Drug: AMG 706 placebo; Bevacizumab and 2 more · For: Breast Neoplasms; Breast Tumors; Breast Cancer and 1 more
- A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLCPivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT00369070 · 186 participants · Start Jan 31, 2007 · Primary completion Apr 23, 2008
Drug: Bevacizumab; AMG 706 and 2 more · For: Advanced Non-squamous NSCLC
AmgenAmgen (AMGN)
NCT00121628 · 184 participants · Start Jul 2005 · Primary completion Nov 2006
Drug: AMG 706 · For: Thyroid Cancer
- Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast CancerPivotal-lookingCompleted
Geron CorporationIndustry
NCT01256762 · 166 participants · Start Nov 2010 · Primary completion Oct 2012
Drug: Imetelstat sodium; Bevacizumab and 1 more · For: Locally Recurrent or Metastatic Breast Cancer
Sites: Huntsville, Alabama; Berkeley, California; Campbell, California · 55 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- platelet count decreased29
- haemoglobin decreased27
- thrombocytopenia24
- cytopenia20
- neutropenia17
- neutrophil count decreased11
- white blood cell count decreased10
- infusion related reaction9
- death8
- dyspnoea7
- pancytopenia7
- drug ineffective6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 41 |
| 2025 | 113 |
| 2026 | 32 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rytelo (Imetelstat Sodium)
2024 spending
$1.7M
Beneficiaries
22
55 claims
Per beneficiary
$78,538
$3,704.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,727,835 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U, Santini V, Fenaux P, et al. · Lancet 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia.
Bruedigam C, Porter AH, Song A, et al. · Nat Cancer 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
- Outcomes with imetelstat in myelofibrosis: a systematic review and meta-analysis.
Shahzad M, Javed HMH, Mannan MS, et al. · Leuk Lymphoma 2025 · Systematic Review, Meta-Analysis
- Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT, Sun L, Mascarenhas J, et al. · Ann Hematol 2022 · Clinical Trial, Comparative Study
- US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.
Kim N, Pulte ED, Ehrlich LA, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.
- Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. · N Engl J Med 2015 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Geron
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.